SCHEMBL30950246

SCHEMBL30950246

Fc1cc(Cl)cc2c1cnn2C1CCCCO1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.45
▸ CYP4A11 Q02928 2/20 0.45
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ RXRG P48443 1/20 0.42
▸ LMNA P02545 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ PDE1A P54750 2/20 0.34
▸ PDE1B Q01064 2/20 0.34
▸ PDE1C Q14123 2/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ YTHDC1 Q96MU7 1/20 0.33
▸ DGAT2 Q96PD7 1/20 0.33
▸ PDE9A O76083 2/20 0.33
▸ ATR Q13535 4/20 0.33
▸ RET P07949 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ IDH1 O75874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21196196 1.00 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL21196054 0.86 CYP4F2 (0.46) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29921466 0.84 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20699355 0.84 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL17731741 0.84 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL25413737 0.84 RXRA (0.44) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29561854 0.84 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29921383 0.82 CYP4F2 (0.43) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL28575619 0.82 CYP4F2 (0.43) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL21195846 0.82 CYP4F2 (0.42) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055363-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2026-05-15 — — CN disclosed
EP-4735440-A1 KRAS INHIBITORS Bristol-Myers Squibb Company (US) 2026-05-06 — — EP disclosed
EP-4735439-A1 KRAS INHIBITORS Bristol-Myers Squibb Company (US) 2026-05-06 — — EP disclosed
EP-4724438-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2026-04-15 — — EP disclosed
WO-2025006962-A1 KRAS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-01-02 — — WO disclosed
WO-2025006967-A1 KRAS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-01-02 — — WO disclosed
WO-2024259015-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-12-19 — — WO disclosed
CN-113637005-B KRAS inhibitors for cancer treatment 泰励生物科技(上海)有限公司 2024-05-24 — — CN disclosed
Send feedback